Skip to main content
Arvee Laboratories (India) Limited logo

Arvee Laboratories (India) Limited — Investor Relations & Filings

Ticker · ARVEE ISIN · INE006Z01016 LEI · 33580075Q2EAWYCO4C50 National Stock Exchange of India Manufacturing
Open in API
Filings indexed 280 across all filing types
Latest filing 2023-01-31 Regulatory Filings
Country IN India
Listing National Stock Exchange of India ARVEE

About Arvee Laboratories (India) Limited

http://arveelabs.com/

Arvee Laboratories (India) Limited specializes in the manufacturing and export of specialty chemicals and pharmaceutical intermediates. The company focuses on the production of high-quality chemical compounds, including Dimethyl 5-Sulfoisophthalate Sodium Salt (DMSIP), 5-Sulfoisophthalic Acid Monosodium Salt, and various other aromatic intermediates. These products serve as critical components in the textile, polymer, and pharmaceutical sectors. Arvee Laboratories emphasizes research and development to enhance its chemical synthesis processes and maintain international quality standards. Its operations involve complex chemical reactions such as sulfonation, esterification, and reduction, catering to a diverse global clientele requiring specialized chemical solutions for industrial applications.

Recent filings

Filing Released Lang Actions
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate submitted under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, confirming no dematerialization requests for equity shares during the quarter ended September 30, 2022. It is a compliance certificate from the Registrar and Transfer Agent to the stock exchange. The document length is short (2711 characters) and it is a regulatory compliance certificate rather than a financial report or announcement of financial results. It does not contain financial statements or detailed financial data. Therefore, it fits best under Regulatory Filings (RNS) as it is a regulatory compliance document and not a report or announcement of a report.
2023-01-31 English
Board Meeting — Financial Results/Other business matters
Board/Management Information Classification · 95% confidence The document is a notification titled 'Intimation of Board Meeting' addressed to the National Stock Exchange of India. It informs about a scheduled Board of Directors meeting to consider unaudited quarterly results. The content is an announcement of a board meeting and related procedural information, not the actual financial report or detailed management discussion. The document is short (1825 characters) and serves as a regulatory announcement about an upcoming board event, consistent with a Board/Management Information filing.
2023-01-23 English
Disclosure under SEBI Takeover Regulations
Major Shareholding Notification Classification · 100% confidence The document is a report filed under Regulation 10(6) of the Securities and Exchange Board of India (SEBI) (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. It details an inter-se transfer of shares within the promoter group of Arvee Laboratories (India) Limited, specifying the number of shares transferred, the parties involved, and the regulatory basis for exemption from an open offer. The content focuses on disclosure of a substantial acquisition of shares and compliance with takeover regulations, which aligns with notifications about major shareholding changes. There is no indication of financial statements, earnings data, or management commentary. The document is not an announcement of a report but the actual regulatory disclosure of a shareholding change. Therefore, the appropriate classification is Major Shareholding Notification (MRQ).
2022-12-30 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a letter from Arvee Laboratories (India) Limited addressed to the National Stock Exchange of India Limited. It informs about the closure of the trading window for dealing in the company's securities from January 1, 2023, until 48 hours after the declaration of quarterly results for the period ended December 31, 2022. The letter is signed by the Company Secretary and Compliance Officer. The content is a regulatory announcement related to insider trading compliance and trading restrictions, not a financial report or detailed disclosure. The document length is short (1721 characters) and it does not contain financial data or detailed report content. Therefore, it is best classified as a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2022-12-29 English
Disclosure under SEBI Takeover Regulations
Regulatory Filings
2022-12-19 English
Price movement
Regulatory Filings
2022-12-08 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.